Community post

A new preprint by Dr. Aleksandra Petrovic Fabijan and colleagues at the Westmead Institute for Medical Research in Sydney, Australia and AmpliPhi Biosciences provides much-awaited data from their IV phage therapy treatment of 13 patients with severe Staphylococcus aureus infections. They saw no adverse effects, bacterial burden and inflammation was reduced, and no phage-resistant S. aureus were isolated. Please comment on / discuss their preprint here!